Deals of the Week! is on vacation. See you in August.image from flickr user cdevers used under a creative comons license
skip to main |
skip to sidebar
Blog Archive
-
▼
2009
(463)
-
▼
July
(30)
- The Effient Launch: Cracking the Door to Primary-C...
- Financings of the Fortnight: Sunshine Breaking Thr...
- Viehbacher on R&D: Smaller Teams "Not Enough"
- While You Weren't in Cooperstown...
- We Interrupt Your Regularly Scheduled Deals of the...
- The NICE Report: A Curate's Egg?
- Bristol’s Poker Game: Doubling-Down on Research
- NICE Should Keep QALY
- Survey Says More FOB Negotiation Needed
- Have a NICE Day: Look out for Report on Value-Asse...
- While You Were Moonstruck
- DotW: Do Deals Finish the Race?
- The Importance of Health to Health Care Reform
- The Next Phase For Regenerative Medicine: New Advo...
- Financings of the Fortnight: Summer Madness
- Germany Gets Creative with Pharmaco-Payer Contracts
- Romance, Drama, Pharma: Pharmedy Tonight
- Stuck at NICE? Flash your Innovation Pass
- Follow-On Blackjack: Place Your Exclusivity Bets
- The End of Generics as We Know 'Em
- While You Were Summering
- DotW: Singing in the Rain
- What's a Biodollar Worth? Let's Ask Vertex
- D-mab Trumps Zometa With Top-Line Cancer Results
- Lobbying and Health Reform: Reading Between the Lines
- While You Were Pursuing Happiness
- Novo Hopes Victoza’s EU Clearance Bodes Well for US
- DOTW: Fireworks
- J&J Buys Elan Out of a Jam
- The IN VIVO Blog Podcast: An Inside View of Biotec...
-
▼
July
(30)
Followers
Total Pageviews